Abstract
Swallow optimized IMRT is now supported by level 1 evidence from the phase III DARS trial (CRUK/14/014). By avoiding non-target RT dose to the pharyngeal constrictors, dysphagia optimized IMRT achieved mean MDADI score 7.2 points lower than conventional IMRT as 12 months. What does this mean? Is this a meaningful difference in swallowing function? Will the functional gain be durable into the second decade of survivorship?After a primer on radiation-associated dysphagia in oropharyngeal cancer, the presenter will pragmatically interpret the DARS results from the perspective of a dysphagia specialist - including implications for supportive care. DARS results will be put into context of contemporary function-sparing trials in oropharynx cancer.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
